Dec 18, 2019
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
1,047
Dec 1, 2019
NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Kd This...
328
Dec 31, 2018
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
(LINKER-MM1) RRMM First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma The primary objectives...
806
Dec 30, 2018
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS
CEPHEUS Study MMY3019 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE,...
1,626
Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
400
Dec 29, 2005
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
CALGB 100104 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101: Phase 3 -...
426